CN1198817C - 作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺 - Google Patents

作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺 Download PDF

Info

Publication number
CN1198817C
CN1198817C CNB99812236XA CN99812236A CN1198817C CN 1198817 C CN1198817 C CN 1198817C CN B99812236X A CNB99812236X A CN B99812236XA CN 99812236 A CN99812236 A CN 99812236A CN 1198817 C CN1198817 C CN 1198817C
Authority
CN
China
Prior art keywords
compound
alkyl
aryl
unsubstituted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB99812236XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1323302A (zh
Inventor
R·沃林
S·B·罗森布鲁姆
A·阿丰索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1323302A publication Critical patent/CN1323302A/zh
Application granted granted Critical
Publication of CN1198817C publication Critical patent/CN1198817C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB99812236XA 1998-10-16 1999-10-15 作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺 Expired - Fee Related CN1198817C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/173642 1998-10-16
US09/173,642 US6133291A (en) 1998-10-16 1998-10-16 N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists

Publications (2)

Publication Number Publication Date
CN1323302A CN1323302A (zh) 2001-11-21
CN1198817C true CN1198817C (zh) 2005-04-27

Family

ID=22632924

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB99812236XA Expired - Fee Related CN1198817C (zh) 1998-10-16 1999-10-15 作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺

Country Status (10)

Country Link
US (1) US6133291A (https=)
EP (1) EP1121354B1 (https=)
JP (1) JP2002527513A (https=)
CN (1) CN1198817C (https=)
AT (1) ATE284398T1 (https=)
AU (1) AU1092800A (https=)
CA (1) CA2346436A1 (https=)
DE (1) DE69922528T2 (https=)
ES (1) ES2229782T3 (https=)
WO (1) WO2000023438A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361666B2 (en) 1999-05-25 2008-04-22 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
US6635661B2 (en) 2000-05-25 2003-10-21 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
US6677332B1 (en) 1999-05-25 2004-01-13 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
US6645980B1 (en) 2000-05-25 2003-11-11 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
US6476050B2 (en) 2000-03-14 2002-11-05 Sepracor, Inc. 3-substituted piperidines comprising urea functionality, and methods of use thereof
ATE283853T1 (de) * 2000-09-20 2004-12-15 Schering Corp Substituierte imidazole als duale histamine h1 und h3 agonisten oder antagonisten
FR2827863A1 (fr) * 2001-07-27 2003-01-31 Sanofi Synthelabo Derives d'aminoalkylimidazole, leur preparation et leur utilisation en therapeutique
KR100432577B1 (ko) 2002-02-08 2004-05-24 주식회사유한양행 이미다졸 유도체의 제조방법
PT1499316E (pt) * 2002-04-18 2008-06-30 Schering Corp Derivados de (1-4-piperidinil)benzimidazole úteis como antagonistas de histamina h3
WO2004000831A1 (en) * 2002-06-24 2003-12-31 Schering Corporation Indole derivatives useful as histamine h3 antagonists
US7880017B2 (en) 2003-11-11 2011-02-01 Allergan, Inc. Process for the synthesis of imidazoles
US7183305B2 (en) 2003-11-11 2007-02-27 Allergan, Inc. Process for the synthesis of imidazoles
EP1896453B1 (en) * 2005-06-20 2009-12-02 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
CL2007002958A1 (es) * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
WO2009076512A1 (en) 2007-12-11 2009-06-18 Epix Delaware, Inc. Carboxamidξ compounds and their use as chemokine receptor agonists
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10752588B2 (en) * 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006137A (en) * 1975-08-21 1977-02-01 E. R. Squibb & Sons, Inc. 2-Ethenyl imidazolium derivatives
ZA792608B (en) * 1978-05-30 1980-06-25 Smith Kline French Lab Nitro compounds
JPS6287573A (ja) * 1985-10-11 1987-04-22 Banyu Pharmaceut Co Ltd 四級アンモニウム塩の製造法
GB8916947D0 (en) * 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
GB9115740D0 (en) * 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
DE69212164T2 (de) * 1991-12-18 1996-12-05 Schering Corp., Kenilworth, N.J. Imidolylalkyl-derivate substituiert mit einem stickstoffenthaltende-6 gliedrigen ring
MX9207393A (es) * 1991-12-18 1994-06-30 Schering Corp Imidazoil o alquilo de imidazoil susbtituido con una cadena heterociclica de cuatro o cinco miembros que contienen nitrogeno.
WO1993012093A1 (en) * 1991-12-18 1993-06-24 Schering Corporation Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
US5807872A (en) * 1992-12-16 1998-09-15 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
FI92843C (fi) * 1993-02-25 1995-01-10 Eija Anitta Maeensivu Uusi menetelmä optisesti aktiivisten glyserolijohdannaisten valmistamiseksi
ATE234290T1 (de) * 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
DK0841923T3 (da) * 1995-06-07 2003-01-27 Gliatech Inc 1H-4(5)-substituerede imidazolderivater

Also Published As

Publication number Publication date
ES2229782T3 (es) 2005-04-16
WO2000023438A1 (en) 2000-04-27
US6133291A (en) 2000-10-17
JP2002527513A (ja) 2002-08-27
EP1121354A1 (en) 2001-08-08
EP1121354B1 (en) 2004-12-08
AU1092800A (en) 2000-05-08
CN1323302A (zh) 2001-11-21
CA2346436A1 (en) 2000-04-27
ATE284398T1 (de) 2004-12-15
DE69922528T2 (de) 2005-12-15
DE69922528D1 (de) 2005-01-13

Similar Documents

Publication Publication Date Title
CN1198817C (zh) 作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺
CN1273450C (zh) 作为5－羟色胺－6配体的1－芳基或1－烷基磺酰基吲哚衍生物
CN100351236C (zh) 用作5－羟色胺－6配体的1－杂环基烷基－3－磺酰基－吲哚衍生物，其制备方法和用途
CN1072669C (zh) 苯并咪唑化合物及其用作gabaa受体复合物调节器的用途
CN1720225B (zh) 具有5-羟色胺受体亲和性的n-芳基磺酰-3-取代吲哚及其制备方法和含有其的药物组合物
CN1451007A (zh) 腺苷A2a受体拮抗剂
US20110059935A1 (en) Beta-LACTAMYL VASOPRESSIN V1a ANTAGONISTS
CN1141043A (zh) 非肽类速激肽受体拮抗剂
CN1478087A (zh) 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
CN1349524A (zh) 血管紧张肽原酶抑制剂
CN1649845A (zh) 蝇蕈碱拮抗剂
CN1146559C (zh) 毒蕈碱性拮抗剂
CN1182425A (zh) 苯并咪唑化合物及其用作gabaa受体复合物调节器的用途
CN1492863A (zh) 作为5-羟色胺-6配基的杂环基烷基-吲哚或氮杂吲哚化合物
CN1437596A (zh) 苯基哌嗪基衍生物
CN1112923C (zh) 吲唑甲酰胺
AU2002342045A1 (en) Beta-lactamyl vasopressin Vla antagonists
CN1264847C (zh) 1－氧杂－3,9－二氮杂－螺[5.5]十一－2－酮衍生物及其作为神经激肽受体拮抗剂的用途
CN1461304A (zh) 作为双组织胺h1和h3促效剂或拮抗剂的取代的咪唑类化合物
CN1461303A (zh) 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑
HK1040706A1 (zh) Fkbp抑制剂
CN1285828A (zh) 被含有一个氮原子的五、六或七元杂环取代的咪唑基烷基
CN1875016A (zh) 咪唑衍生物
CN1558907A (zh) 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑
WO2005035492A1 (en) 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee